Malaria Immunology and Vaccine Development

Malaria remains one of the most pressing global health challenges, with Plasmodium falciparum and Plasmodium vivax causing the majority of morbidity and mortality. Immunological control of malaria involves a complex interplay between innate defences, antibody-mediated (humoral) responses and T cell-mediated (cellular) mechanisms. In the pre-erythrocytic stage, sporozoites injected by mosquitoes are targeted by antibodies and cytotoxic T lymphocytes in the skin and liver, while in the erythrocytic stage merozoites invading red blood cells are neutralised by opsonising antibodies and phagocytes. Naturally acquired partial immunity develops over repeated exposures, yet antigenic diversity and immune-evasion strategies of the parasite have impeded durable vaccine protection. Recent advances in structural biology, high-throughput immunoprofiling and rational antigen design have informed next-generation candidates, from multistage chimeric proteins to lipid-adjuvanted subunit formulations. Pre-clinical and early-phase clinical studies now address immunogenicity, safety and correlates of protection, aiming to combine breadth of antigenic coverage with potent cellular and humoral responses. Integrating insights from molecular structure, host–parasite interactions and population immunology promises to overcome past obstacles and guide the rational development of effective, durable vaccines for endemic and non-endemic settings alike.

Research from Nature Portfolio

Structural analysis of a Plasmodium vivax tryptophan-rich antigen domain has revealed a three-helical bundle with lipid-binding properties, suggesting a conserved role in merozoite invasion of reticulocytes. This work elucidates a new functional class within a pan-Plasmodium gene family and identifies sulphatide recognition as a potential target for vaccine-directed antibodies. In parallel, a comprehensive review of immune effector mechanisms outlines how antigen presentation, B cell maturation and CD8+ T cell responses coordinate to regulate parasite replication. By dissecting correlates of protective immunity and mapping antigenic targets across life-cycle stages, this synthesis provides a manifesto for rational design of next-generation vaccines with improved efficacy profiles.

Malaria Immunology and Vaccine Development publication trend

The graph below shows the total number of articles in malaria immunology and vaccine development across all publications each year (not limited to Nature Index journals).

Technical terms

Sporozoite: The motile parasite form transmitted by mosquitoes, which infects hepatocytes in the liver.

Merozoite: The blood-stage parasite form that emerges from infected hepatocytes and invades red blood cells.

Pre-erythrocytic stage: The phase of infection when parasites develop in the liver prior to blood-stage invasion.

Adjuvant: A compound included in vaccine formulations to enhance and shape the immune response to the antigen.

Immunogenicity: The capacity of a vaccine component or pathogen antigen to elicit an immune response.

Antigenic diversity: The genetic and structural variation in parasite proteins that enables evasion of host immunity.

References

1. The structure of a Plasmodium vivax Tryptophan Rich Antigen domain suggests a lipid binding function for a pan-Plasmodium multi-gene family. Nature Communications (2023).
2. Immune mechanisms in malaria: new insights in vaccine development. Nature Medicine (2013).
3. Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial. Frontiers in Immunology (2023).
4. Construction, Expression, and Evaluation of the Naturally Acquired Humoral Immune Response against Plasmodium vivax RMC-1, a Multistage Chimeric Protein. International Journal of Molecular Sciences (2023).
5. High-Throughput Antibody Profiling Identifies Targets of Protective Immunity against P. falciparum Malaria in Thailand. Biomolecules (2023).